<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Best Of Week - Head &amp; Neck Cancer</title>
    <link>https://pubmed.ncbi.nlm.nih.gov</link>
    <description>Top 10 most impactful head and neck cancer papers this week, selected by AI</description>
    <lastBuildDate>Tue, 17 Feb 2026 06:48:19 +0000</lastBuildDate>
    <item>
      <title>#1 [90/100] Final survival analysis of induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: a multicenter, randomized, phase 3 trial.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41667463/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41667463/</guid>
      <dc:creator>Cao X, Zhou JY, Huang HY, Guo L, Huang YY, Qiu WZ, Lin ZC, Cao KJ, Mo HY, Li XM, et al.</dc:creator>
      <pubDate>Tue, 10 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;ðŸ”¥ CRITICAL - Score: 90/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This multicenter, randomized phase 3 trial provides definitive evidence comparing lobaplatin to cisplatin in nasopharyngeal carcinoma, demonstrating non-inferior survival with fewer toxic effects, which has significant implications for treatment guidelines and patient quality of life.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Cao X, Zhou JY, Huang HY, Guo L, Huang YY, Qiu WZ, Lin ZC, Cao KJ, Mo HY, Li XM, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Nature communications | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1038/s41467-026-69315-1'&gt;10.1038/s41467-026-69315-1&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-10&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41667463/'&gt;41667463&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;In nasopharyngeal carcinoma, cisplatin is known to be associated with poor treatment compliance and notable side effects. More effective and safer platinum drugs are needed for the treatment of patients with nasopharyngeal carcinoma. In 2021, our multicenter, randomized, phase 3 trial reported that lobaplatin and fluorouracil induction chemotherapy plus concurrent chemoradiotherapy resulted in non-inferior survival and fewer toxic effects than did cisplatin-based therapy in nasopharyngeal carcinoma. Data from the 10-year survival analysis are updated here. With a median follow-up of 10.6 years in the intention-to-treat population, 10-year progression-free survival is 70.7% in the lobaplatin-based therapy group vs. 71.9% in the cisplatin-based therapy group (HR 1.02, 95% CI 0.72-1.43; log-rank pâ€‰=â€‰0.885). The difference between the groups is 1.2% (95% CI -6.7-9.1, pnon-inferiorityâ€‰=â€‰0.015), which is lower than the prespecified non-inferiority margin of 10%. The results are similar when we analyze patients in the per-protocol population. In the univariable and multivariable analyses, stage is an independent prognostic factor for progression-free survival (pâ€‰=â€‰0.001). The subgroup analyses suggest that the non-inferiority of lobaplatin-based therapy did not differ among specific populations. The incidence of late toxic effects is similar between the therapy groups, exceptÂ for grades 1-2 peripheral neuropathy (pâ€‰=â€‰0.033), grades 1-2 deafness/otitis (pâ€‰=â€‰0.021), and grades 1-2/3 nephrotoxicity (pâ€‰=â€‰0.005; pâ€‰=â€‰0.021), the incidence of which is greater in the cisplatin-based therapy group than in the lobaplatin-based therapy group. Our findings suggest that lobaplatin and fluorouracil induction chemotherapy plus lobaplatin-based concurrent chemoradiotherapy is an alternative doublet treatment strategy to cisplatin-based concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.</description>
    </item>
    <item>
      <title>#2 [90/100] Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41667193/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41667193/</guid>
      <dc:creator>You R, Xu GQ, Ding X, Liang JH, Liu ZG, Zou X, Liu YP, Hu GY, Liu YM, Duan CY, et al.</dc:creator>
      <pubDate>Tue, 10 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;ðŸ”¥ CRITICAL - Score: 90/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This multicentre, randomized, open label, phase 3 trial evaluates the addition of camrelizumab to standard chemoradiotherapy in high-risk nasopharyngeal carcinoma, representing a potential paradigm shift in treatment and published in a reputable journal, indicating high clinical relevance and impact.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; You R, Xu GQ, Ding X, Liang JH, Liu ZG, Zou X, Liu YP, Hu GY, Liu YM, Duan CY, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; BMJ (Clinical research ed.) | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1136/bmj-2025-085863'&gt;10.1136/bmj-2025-085863&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-10&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41667193/'&gt;41667193&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: To assess treatment with camrelizumab (a programmed death 1 inhibitor) in addition to concurrent chemoradiotherapy and as a maintenance treatment in patients with high risk nasopharyngeal carcinoma. DESIGN: Multicentre, randomised, open label, phase 3 trial. SETTING: Seven hospitals in China between 18 August 2020 and 21 June 2022. PARTICIPANTS: Adults aged 18-70 years with newly diagnosed high risk nasopharyngeal carcinoma after three cycles of induction chemotherapy with gemcitabine and cisplatin (stage 4a, stage 2-3 with stable or progressive disease, or detectable Epstein-Barr virus DNA). INTERVENTIONS: Patients were randomly assigned (1:1) to receive combination chemoradiotherapy based on cisplatin (standard treatment group) or standard treatment with 19 cycles of intravenous camrelizumab (200 mg) once every three weeks (radiotherapy plus two concurrent cycles and 17 adjuvant cycles; camrelizumab group). MAIN OUTCOME MEASURES: The primary endpoint in the intention-to-treat group was progression-free survival, defined as the time from randomisation to disease recurrence (locoregional or distant) or death from any cause. Secondary endpoints included safety and overall survival. RESULTS: 390 patients were enrolled and randomly assigned to the camrelizumab group (n=194) or the standard treatment group (n=196). At median follow-up of 39.9 months (interquartile range 36.8-43.4 months), progression-free survival was higher in the camrelizumab group than the standard treatment group (36 months: 83.4%, 95% confidence interval 78.3% to 88.8% v 71.3%, 65.2% to 77.9%; stratified hazard ratio 0.51, 95% confidence interval 0.34 to 0.77, P=0.001). The incidence of acute and late adverse events (grade 3 or 4) was 50.5% and 3.2% in the camrelizumab group compared with 48.7% and 3.7% in the standard treatment group. Immunological adverse events (grade 3 or 4) occurred in 19 patients (10.2%) in the camrelizumab group. CONCLUSION: The addition of camrelizumab to concurrent chemoradiotherapy and as a maintenance treatment improved progression-free survival among patients with high risk nasopharyngeal carcinoma after induction chemotherapy. TRIAL REGISTRATION: ClinicalTrials.gov NCT04453826.</description>
    </item>
    <item>
      <title>#3 [75/100] Proposed Version Nine of the AJCC and UICC TNM Classification for Salivary Gland Carcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41678147/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41678147/</guid>
      <dc:creator>Huang SH, Cotler J, Palis B, Seethala RR, Hosni A, O'Sullivan B, Vander Poorten V, Bishop JA, Glastonbury CM, Beadle B, et al.</dc:creator>
      <pubDate>Thu, 12 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;âœ¨ NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study proposes a novel pTNM classification for salivary gland carcinoma, which could improve prognostic accuracy and clinical decision-making. While it utilizes a large dataset for validation, it is a retrospective study and does not present practice-changing findings but offers important advancements in staging.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Huang SH, Cotler J, Palis B, Seethala RR, Hosni A, O'Sullivan B, Vander Poorten V, Bishop JA, Glastonbury CM, Beadle B, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; JAMA otolaryngology-- head &amp; neck surgery | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1001/jamaoto.2025.5396'&gt;10.1001/jamaoto.2025.5396&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-12&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41678147/'&gt;41678147&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;IMPORTANCE: A unified salivary gland carcinoma (SGC)-specific tumor-node-metastasis (TNM) classification can enhance prognostic accuracy, support clinical decision-making, and improve the quality of patient care. OBJECTIVE: To derive and validate an SGC-specific pTNM classification with improved prognostic accuracy and optimized stage distribution for version nine of the American Joint Committee on Cancer/Union for International Cancer Control staging protocol. DESIGN, SETTING, AND PARTICIPANTS: This retrospective prognostic cohort study derived a novel pTNM classification using data from the National Cancer Database (NCDB) of patients with surgically treated major SGC (2012-2017) and validated it in an international major SGC cohort (2008-2021) and a single-institution minor SGC cohort (Memorial Sloan Kettering Cancer Center; 1985-2016). Data were analyzed from June to November 2024. EXPOSURES: Surgery with or without postoperative radiotherapy or chemoradiotherapy. MAIN OUTCOMES AND MEASURES: The primary end point was overall survival (OS). Cox proportional hazards multivariable analysis was used to confirm the prognostic importance of pathologically positive lymph node (LN) number and extranodal extension (pENE) and derive an optimal pTNM classification. RESULTS: The NCDB dataset included 8409 patients with SGC: 7659 with M0 disease (5748 with pN0 disease and 1911 with pN+ disease) and 750 with M1 disease. Among the 7659 patients with M0 disease, the median (IQR) age was 60 (48-71) years, and 3861 (50.4%) were male. The median (IQR) follow-up was 88.4 (72.3-108.5) months. The 5-year OS was 87.2% (95% CI, 86.3-88.0) for N0 disease, 68.2% (95% CI, 63.9-72.8) for 1 positive LN without pENE, 60.2% (95% CI, 53.5-67.5) for 2 positive LNs without pENE, 68.4% (95% CI, 58.0-76.6) for 3 positive LNs without pENE, 47.5% (95% CI, 41.6-52.8) for more than 3 positive LNs without pENE, and 41.4% (38.1-44.8) for pENE-positive LNs. Multivariable analysis confirmed the independent prognostication of LN count compared with pN0 disease (1 positive LN: adjusted hazard ratio [aHR], 1.70; 95% CI, 1.44-2.01; 2 positive LNs: aHR, 1.61; 95% CI, 1.31-1.98; 3 positive LNs: aHR, 2.10; 95% CI, 1.65-2.68; 4 positive LNs : aHR, 2.46; 95% CI, 1.87-3.24; more than 4 positive LNs: aHR, 2.07; 95% CI, 2.08-2.91) and pENE-positive LNs compared with pENE-negative LNs (aHR, 1.27; 95% CI, 1.10-1.48). The proposed pN classification were pN1 for 1 to 3 positive LNs and pENE negativity and pN2 for more than 3 positive LNs or pENE positivity. Model fit improved with the proposed pN classification vs the current pN classification (Akaike Information Criterion, 26â€¯442 vs 26â€¯483). Based on the aHR model, the following stage groups were proposed: stage I: T1N0 (1 [reference]); stage II: T2N0 (aHR, 1.34; 95% CI, 1.11-1.61); stage IIIA: T1-2N1 or T3-4N0 (aHR, 2.36; 95% CI, 1.99-2.80); stage IIIB: T1-2N2 or T3-4N1-2 (aHR, 5.15; 95% CI, 4.38-6.06); and stage IV: M1 disease (aHR, 13.61; 95% CI, 11.37-16.29). The C index values were similar (proposed classification: 0.792; current classification: 0.790), while the AIC improved slightly (proposed classification: 26â€¯441; current classification: 26â€¯482). Stage-specific OS differences were evident in both the international major SGC cohort (nâ€‰=â€‰1015) and Memorial Sloan Kettering Cancer Center minor SGC cohort (nâ€‰=â€‰444). CONCLUSIONS AND RELEVANCE: This unified, SGC-specific staging system improved prognostic accuracy and sample size balance and was applicable to both major and minor SGCs.</description>
    </item>
    <item>
      <title>#4 [75/100] Bridging the Gap: What We Can Learn From LEAP-010 in Recurrent/Metastatic Head and Neck Cancer.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41671524/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41671524/</guid>
      <dc:creator>Xiang J, Geiger JL</dc:creator>
      <pubDate>Wed, 11 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;âœ¨ NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; The paper discusses insights from a significant trial in recurrent/metastatic head and neck cancer, published in a high-impact journal, which may provide important clinical implications and novel insights, although it does not present new primary data or findings.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Xiang J, Geiger JL&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Journal of clinical oncology : official journal of the American Society of Clinical Oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1200/JCO-25-02640'&gt;10.1200/JCO-25-02640&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-11&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41671524/'&gt;41671524&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;i&gt;No abstract available&lt;/i&gt;</description>
    </item>
    <item>
      <title>#5 [70/100] A nurse-led telephone clinic can safely triage suspected head and neck cancer referrals using the head and neck risk calculator.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41699247/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41699247/</guid>
      <dc:creator>North AS, Courtney-Wickes C, Jacob T</dc:creator>
      <pubDate>Mon, 16 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;âœ¨ NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study evaluates a nurse-led telephone triage clinic using a risk calculator in a large prospective service evaluation, which may improve referral efficiency and patient management in head and neck cancer, though it does not present groundbreaking findings or a paradigm shift.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; North AS, Courtney-Wickes C, Jacob T&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1007/s00405-026-10023-3'&gt;10.1007/s00405-026-10023-3&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-16&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41699247/'&gt;41699247&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;PURPOSE: To evaluate the safety and effectiveness of a nurse-led telephone triage clinic, utilising the Head and Neck Cancer Risk Calculator version 2 (HaNC-RC-v2) with consultant oversight, for patients referred on the UK two-week wait (2WW) pathway for suspected head and neck cancer. METHODS: A prospective service evaluation was conducted in a UK hospital receivingâ€‰~â€‰5000 2WW referrals annually. Between November 2023 and March 2025, 2,556 patients underwent telephone triage. Patients scoringâ€‰â‰¥â€‰2.2% on HaNC-RC-v2 remained on the 2WW pathway; those scoringâ€‰&lt;â€‰2.2% were considered for downgrade to a 6-week review following consultant review of their case. Patients referred with an investigation showing a thyroid nodule suspicious for malignancy were sent straight-to-test for ultrasound-guided biopsy. Diagnostic performance was assessed using histologically confirmed malignancy as the reference standard. RESULTS: Of 2,556 triaged patients, 67 (2.6%) had cancer. At the 2.2% cut-off, 16.6% (424/2556) were downgraded, with 3 cancers later diagnosed (0.7%; 3/424). The overall negative predictive value was 99.3% with overall potential harm in 0.12% of all referrals. The straight-to-test pathway diagnosed 14 thyroid cancers (11.6%; 14/121) with shorter mean time to diagnosis (45.3 vs. 56.5 days). CONCLUSION: A nurse-led telephone triage clinic using HaNC-RC-v2 safely downgraded low-risk patients with minimal harm while maintaining a high negative predictive value. Incorporating straight-to-test improved cancer detection and expedited diagnosis. This pathway may enhance service efficiency in managing the increasing volume of suspected cancer referrals across various healthcare systems.</description>
    </item>
    <item>
      <title>#6 [70/100] Multicenter Clinical Validation of an Artificial Intelligence Diagnostic Classification Model for Laryngoscopy Images.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41696998/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41696998/</guid>
      <dc:creator>Sampieri C, Mora F, Peretti G, Larrosa M, Vilaseca I, AvilÃ©s-Jurado FX, Ioppi A, Bellini E, Alegre B, Ruiz-Sevilla L, et al.</dc:creator>
      <pubDate>Mon, 16 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;âœ¨ NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This multicenter study validates an AI diagnostic model for laryngeal lesions using a substantial dataset, providing important insights into risk classification, though it is retrospective and not a randomized controlled trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Sampieri C, Mora F, Peretti G, Larrosa M, Vilaseca I, AvilÃ©s-Jurado FX, Ioppi A, Bellini E, Alegre B, Ruiz-Sevilla L, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/ohn.70153'&gt;10.1002/ohn.70153&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-16&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41696998/'&gt;41696998&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: To develop and externally validate a computer-aided diagnosis (CADx) model using artificial intelligence (AI) for classifying laryngeal lesions from laryngoscopy images into high-risk (HR), low-risk (LR). STUDY DESIGN: Retrospective multicenter development of a CADx model and external validation on independent cohorts. SETTING: Multicenter tertiary referral hospitals (Italy, India, China, Greece, and Spain). METHODS: Over 20,000 images derived from laryngoscopic examinations were retrieved. Images were annotated based on histopathology or expert consensus. A deep learning model was trained using an internal dataset and evaluated on 2 external datasets to assess generalizability. The CADx model classifies only images containing visible lesions, discriminating between LR and HR categories. Diagnostic performance was measured using standard metrics, including accuracy, precision, recall, F1-score, and area under the receiver operating characteristic curve (AUC). Model performance was compared with physicians of varying expertise and ChatGPT-4o. RESULTS: The computer-aided diagnosis model achieved a similar performance across internal and external datasets in distinguishing HR from LR lesions, with accuracy/AUC of 0.90/0.89 internally, 0.85/0.85 on the Greek dataset, and 0.88/0.88 on the Spanish dataset. The model's accuracy was statistically noninferior to that of otolaryngologists and expert laryngologists, and superior to general practitioners and ChatGPT-4o. CONCLUSION: This is a large multicenter clinical validation of a CADx model for laryngeal endoscopy, demonstrating generalizability and performance comparable to clinicians in discriminating between LR and HR lesions. The model's success supports its potential role in augmenting diagnostic capabilities, especially in resource-limited settings. A prospective multicenter clinical trial is underway to assess real-world clinical implementation.</description>
    </item>
    <item>
      <title>#7 [70/100] Does discharge location following head and neck cancer surgery affect quality outcomes?</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41679078/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41679078/</guid>
      <dc:creator>Benites C, White C, Balaguru L, Gonghao L, Lee JH, Conrad DJ, Lam A, Dziegielewski PT</dc:creator>
      <pubDate>Wed, 11 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;âœ¨ NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This is a large retrospective cohort study with nearly 1,900 patients, providing important insights into the impact of discharge location on quality outcomes after head and neck cancer surgery, which could influence clinical practice.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Benites C, White C, Balaguru L, Gonghao L, Lee JH, Conrad DJ, Lam A, Dziegielewski PT&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Oral oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.oraloncology.2026.107879'&gt;10.1016/j.oraloncology.2026.107879&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-11&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41679078/'&gt;41679078&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: Discharge (DC) to post-acute care facilities after head and neck cancer (HNC) surgery is common. Studies in various fields of medicine have shown that DC to facilities is associated with clinical outcomes. Evidence specific to HNC surgery is limited. OBJECTIVES: This study aimed to evaluate how DC, to either home or a facility, impacts outcomes for patients undergoing HNC surgery. METHODS: Retrospective cohort study of patients who underwent HNC surgery between January 1, 2014, and January 1, 2023 was performed. Patients were included based on postoperative hospitalization, surgical interventions, and a minimum 30-day follow-up. The primary outcomes were 30-day readmission, 30-day mortality, and postoperative complication severity. RESULTS: Among 1,895 patients (mean age 63Â years, 67% female), 1,554 (82%) were DC home and 341 (18%) to a facility. After adjusting for significant variables, DC site was not associated with readmission (OR 0.94, 95% CI 0.63-1.40), mortality (0.6% home vs 1.5% facility, pÂ =Â 0.2), or complication severity (mild OR 1.3, pÂ =Â 0.11; severe OR 1.0, pÂ =Â 0.92). Factors such as dependency in activities of daily living, tracheotomy presence, surgery severity and prolonged hospitalization were found to be significant covariates in the multivariable analysis for both 30-day readmissions and complication severity. Facility patients had more infections or wound dehiscence (pÂ &lt;Â 0.05). CONCLUSION: Although DC to a facility was not significantly associated with worsened outcomes in the multivariable analysis, the findings of this study revealed clinically relevant differences in complication rates and readmission.</description>
    </item>
    <item>
      <title>#8 [70/100] A tumor DNA-Methylome derived signature of Hypoxia Identifies HPV-negative head and neck cancer patients at risk for distant metastasis after postoperative radiochemotherapy (PORT-C).</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41672251/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41672251/</guid>
      <dc:creator>Tawk B, Halec G, Rein K, Schwager C, Knoll M, Wirkner U, Held T, Weykamp F, Liermann J, Hoerner-Rieber J, et al.</dc:creator>
      <pubDate>Mon, 09 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;âœ¨ NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study validates a tumor DNA methylation signature in a multicenter cohort of HPV-negative HNSCC patients, providing important insights into predicting distant metastasis after postoperative radiochemotherapy, which could have clinical implications.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Tawk B, Halec G, Rein K, Schwager C, Knoll M, Wirkner U, Held T, Weykamp F, Liermann J, Hoerner-Rieber J, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.radonc.2026.111433'&gt;10.1016/j.radonc.2026.111433&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-09&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41672251/'&gt;41672251&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND AND PURPOSE: Tumor hypoxia is a predictive biomarker of treatment resistance in patients with head and neck squamous cell carcinoma (HNSCC). We previously reported the discovery of a tumor DNA methylation signature of hypoxia (Hypoxia-M), identifying HNSCC patients at risk for local recurrence (LR), all event progression, and death after primary radiochemotherapy (RCHT). We further validate Hypoxia-M in an independent cohort of HNSCC patients who underwent surgical resection followed by postoperative radiochemotherapy (PORT-C) METHODS: Hypoxia-M was validated in HPV-negative HNSCC patients (nÂ =Â 134) homogeneously treated with PORT-C in the frame of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG) multicenter biomarker trial. DNA methylation was profiled using Illumina450K technology. The performance of Hypoxia-M was integrated with previously reported biomarkers, including gene expression signatures (GES) of hypoxia, a methylome-based HPV-Independent Classifier of disease Recurrence (HICR), and immune cell score using immunohistochemistry (CD3/CD8/PD-L1/PD1). RESULTS: Hypoxia-M was independently prognostic for overall survival (OS, HRÂ =Â 2.34, pÂ =Â 0.03) and distant metastasis (DM, HRÂ =Â 4.3, pÂ =Â 0.001), but not for LR after PORT-C. Hypoxia-M remained significant after adjusting for patientÅ› age, gender, smoking status, tumor stage, and high-risk features (ECE&amp;/R1 resection). Hypoxia-M status was inversely associated with CD8 T-cell infiltration. Patient stratification improved by integrating previously reported biomarkers, with Hypoxia-M demonstrating independent prognostic performance. CONCLUSIONS: The prognostic utility of Hypoxia-M was validated in an independent cohort. Our results highlighted a difference in recurrence patterns of hypoxic tumors treated in the primary setting (local recurrence) versus postoperatively (distant metastasis) and the utility of Hypoxia-M for identifying the main pattern of recurrence.</description>
    </item>
    <item>
      <title>#9 [65/100] Network analysis of symptom clusters and core symptom changes in nasopharyngeal cancer survivors: a longitudinal study.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41699334/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41699334/</guid>
      <dc:creator>Li J, Cai W, Wu Q, Tang C, Cao Y, Song Y</dc:creator>
      <pubDate>Mon, 16 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;ðŸ“Œ SELECTED - Score: 65/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This longitudinal study provides valuable insights into symptom clusters in nasopharyngeal cancer survivors, which could inform supportive care practices, but it is based on a moderate sample size and lacks the robustness of a randomized controlled trial or large prospective study.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Li J, Cai W, Wu Q, Tang C, Cao Y, Song Y&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Journal of cancer survivorship : research and practice | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1007/s11764-026-01987-6'&gt;10.1007/s11764-026-01987-6&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-16&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41699334/'&gt;41699334&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;PURPOSE: This study aimed to identify symptom clusters in survivors with nasopharyngeal carcinoma undergoing radiotherapy and to explore the interrelationships among these symptoms. Furthermore, it sought to identify core and bridge symptoms and to observe their changes over time. METHODS: A longitudinal study was conducted, recruiting 181 survivors newly diagnosed with nasopharyngeal carcinoma who were undergoing radiotherapy. Measurements were taken during weeks 1-6 of radiotherapy. Symptom assessment was conducted using the MD Anderson Symptom Assessment Scale - Head &amp; Neck Module. Symptom network analysis was performed at each time point, and centrality metrics were analyzed to explore the interrelationships among symptoms. RESULTS: Four stable symptom clusters were identified, with fatigue, feeling of being distressed, feeling sad, and difficulty swallowing/chewing as central symptoms, and feeling sad, feeling of being distressed, fatigue, and vomiting as bridge symptoms. The stability of the symptom network across the six time points was acceptable. CONCLUSION: The symptom network results are crucial for developing future targeted symptom management interventions. Future research should focus on developing precise interventions targeting core and bridge symptoms to alleviate nasopharyngeal carcinoma survivors' symptom burden. IMPLICATIONS FOR CANCER SURVIVORS: For nasopharyngeal carcinoma survivors undergoing radiotherapy, implementing a dynamic symptom management strategy with tailored interventions for core and bridge symptoms enhances symptom management efficiency, thereby improving survivors' quality of life.</description>
    </item>
    <item>
      <title>#10 [65/100] Contemporary Management of Malignancies of the Parotid Gland: A State-of-the-Art Review.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41696986/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41696986/</guid>
      <dc:creator>Tang A, Helou V, Sridharan SS, Ferrarotto R, Geiger JL, Zandberg DP, Bell D, Skinner H, Spector ME, Myers EN, et al.</dc:creator>
      <pubDate>Mon, 16 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;ðŸ“Œ SELECTED - Score: 65/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This state-of-the-art review synthesizes contemporary management practices for parotid gland malignancies, providing important insights and evidence-based recommendations, but lacks primary research data or novel findings that would significantly alter clinical practice.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Tang A, Helou V, Sridharan SS, Ferrarotto R, Geiger JL, Zandberg DP, Bell D, Skinner H, Spector ME, Myers EN, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/ohn.70170'&gt;10.1002/ohn.70170&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-16&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41696986/'&gt;41696986&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVES: To provide a systematic update on the contemporary management of malignancies of the parotid gland (MPG), focusing on evidence-based practices and emerging therapeutics. DATA SOURCES: PubMed literature search. REVIEW METHODS: A search protocol was designed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) process for articles published between August 1, 2019, and August 1, 2024. Primary exclusion criteria were non-English text, abstracts, and case reports/series. Secondary inclusion criteria were articles specific to MPG diagnosis, histology, outcomes, and management, including surgery, radiotherapy, chemotherapy, immunotherapy, and targeted therapy. CONCLUSION: A total of 1614 articles were identified, and 137 articles were included in the final review. Most studies on low-grade MPG found that surgery alone was noninferior to surgery and adjuvant radiotherapy for local control. Elective neck dissection provided survival benefits for high-grade, but not low-grade, MPG. Most MPG are chemotherapy-resistant. Adjuvant chemotherapy provides limited survival benefits while significantly worsening quality of life and, thus, should be used only in select patients. Immunotherapy and targeted therapies for markers, including HER-2, TRK, and androgen receptors, have shown promising results in the treatment of advanced MPG. IMPLICATIONS FOR PRACTICE: Advances in the treatment of MPG have improved survival while minimizing treatment toxicity and improving quality of life. Future studies are needed to emphasize personalized oncologic treatment for patients with these rare malignancies.</description>
    </item>
  </channel>
</rss>
